Article

Sprung, VS, Kemp, GJ, Wilding, JP, Adams, V, Murphy, K, Burgess, M, Emegbo, S, Thomas, M, Needham, AJ, Weimken, A, Schwab, RJ, Manuel, A, Craig, SE and Cuthbertson, DJ (2020) Randomised, cOntrolled Multicentre trial of 26 weeks subcutaneous liraglutide (a glucagon-like peptide-1 receptor Agonist), with or without contiNuous positive airway pressure (CPAP), in patients with type 2 diabetes mellitus (T2DM) and obstructive sleep apnoEa (OSA) (ROMANCE): study protocol assessing the effects of weight loss on the apnea-hypnoea index (AHI). BMJ Open, 10 (7). ISSN 2044-6055